AzTrials
AzTrials

Severe Traumatic Brain InjuryELASTICNCT05889650

External Lumbar Drainage to Reduce ICP in Severe TBI: a Phase 1 Clinical Trial

A study testing External Lumbar drainage in people with Severe Traumatic Brain Injury and Intracranial Hypertension, run by Brain Trauma Foundation at 6 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this phase 1 randomized controlled safety and feasibility clinical trial are to determine the safety of external lumbar drainage (ELD) in select patients with severe Traumatic Brain Injury (TBI). Read more about this study

Who is it for?
Ages 18 to 65 years
What is being tested?
External Lumbar drainage
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
6 sitesUnited States
Study dates
24 Jun 2024to 30 Jun 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18-65 years age
  • Glasgow Coma Scale (GCS) 3-8
  • Pupils symmetric and bilaterally reactive
  • Midline shift ≤5mm at the level of foramen of Monro on admission or post-operative brain CT
  • Patent (complete or partial) quadrigeminal cisterns on admission or post-operative brain CT
  • First randomization and intervention may be commenced within 24 hours of injury
  • ELD safety score ≥5

Who cannot join

  • GCS >8
  • Cisterns on CT completely effaced
  • Midline shift on CT >5mm
  • GCS 3 with dilated and fixed pupils
  • Uncal or tonsillar herniation on admission or post-operative brain CT
  • Temporal lobe contusions with effaced ipsilateral cisterns
Show all 14Show fewer
  • Penetrating TBI
  • Primary hemicraniectomy
  • Pregnancy
  • Prisoners
  • Patients previously lacking capacity to consent or refuse treatment, or with advanced directives to forego aggressive care
  • Pre-existing conditions affecting functional status or life expectancy to less than 1 year
  • Contra-indications for ELD placement: coagulopathy, use of anticoagulants or anti-thrombotics, thrombocytopenia <50,000, or severe spinal deformity.
  • posterior fossa hemorrhage

Trial locations and contacts

6 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Carlos Morales, MPH contact

240-6536638

carlos.morales.ctr@usuhs.edu

Halinder S Mangat, MD, MSc contact

913-5886970

elastic@braintrauma.org

6 sites in 1 country

United States6 sites, 6 recruiting
  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390

    Alex Valadka, MD, alex.valadka@utsouthwestern.edu

    Aisha Qureshi, Aisha.Qureshi@utsouthwestern.edu

    Recruiting
  • Brooke Army Medical Center

    Fort Sam Houston, Texas, 78234

    Geoffrey Peitz, MD, geoffrey.w.peitz.mil@health.mil

    Ryan Morton, MD, ryan.p.morton.mil@health.mil

    Recruiting
  • University of Florida

    Gainesville, Florida, 32610

    Ivan DaSilva, MD, Ivan.RochaFerreiraDaSilva@neurology.ufl.edu

    Magali Jorand-Fletcher, magali.jorand-fletcher@neurology.ufl.edu

    Recruiting
  • University of Houston Medical Center

    Houston, Texas, 77030

    Ryan Kitagawa, MD, PhD

    Recruiting
  • Kansas University Medical Center

    Kansas City, Kansas, 66160

    Halinder S Mangat, MD, MSc, hmangat@braintrauma.org

    Recruiting
  • University of Texas

    San Antonio, Texas, 78249

    Michael McGinity, MD, mcginity@uthscsa.edu

    Megan Jackson, jacksonm1@uthscsa.edu

    Recruiting

Other trials in United States

About this study

Official title: External Lumbar Drainage to Abort Severe Traumatic IntraCranial Hypertension: A Phase 1 Randomized, Allocation-concealed, Open-label, Safety and Feasibility Clinical Trial

The goal of this phase 1 randomized controlled safety and feasibility clinical trial are to determine the safety of external lumbar drainage (ELD) in select patients with severe Traumatic Brain Injury (TBI). The main questions it aims to answer are (i) if ELD is feasible and (ii) safe to perform in severe TBI patients who have radiological evidence of patent basal cisterns and midline shift <5mm without increasing the risk of neurological worsening or cerebral herniation.

All participants will receive routine usual care. The study group will additionally have ELD for cerebrospinal fluid (CSF) drainage. A comparison will be made between the usual treatment plus ELD (interventional) groups, and the usual treatment (control) groups on incidence rate of neurological worsening or cerebral herniation events, and whether total hours with raised intracranial pressure (ICP) are different.

Read the detailed description

This is a randomized controlled trial to determine the safety and feasibility of external lumbar drainage (ELD) of cerebrospinal fluid (CSF) as an adjunct to existing treatments to lower brain pressure, in select patients suffering severe traumatic brain injury (TBI). This trial is funded by the Department of Defense, Uniformed Services University of Health Sciences, Center for Neuroscience and Regenerative Medicine (CNRM).

Following a severe TBI, the brain swells and the pressure in the cranium rises causing further brain injury, The goal of treatment of such patients is to use treatments that lower brain swelling or pressure - directly by removing blood clots or indirectly by trying to lower the volume of contents in the cranium, viz. CSF or blood. Routinely a drain is placed in the skull to drain CSF out to provide space for brain swelling, thus keeping intracranial pressure (ICP) low. In some instances, all treatments available are unable to control swelling and the skull may need to be removed from one side, and in spite of this patients may die or suffer severe neurological injury and remain disabled.

Several non-randomized studies have shown that ELD is very effective in lowering intracranial pressure (ICP) in an immediate and lasting manner. While historical concerns remain that the brain may shift downwards causing herniation, this is not supported by recent studies. However, due to the historic nature of such teachings, some physicians may not use this potentially effective treatment in treating severe TBI patients with high ICP.

Therefore, in this trial we will determine the safety ELD in treating severe TBI patients, in a randomized controlled manner, whereby two-thirds of the patients will be randomized to routine usual treatments and either early or late ELD, and a third to only routine usual treatments. The patient randomized to ELD will receive this in addition to all other usual treatments, and no available treatment will be withheld

The secondary objectives are to determine if routine quantitative pupillometry can be used for safety determination and monitoring of ELD by evaluating:

  1. Correlation with ELD safety score
  2. Temporally changes prior to occurrence of any 'critical neuro-worsening events

Comparison / Usual treatment All participants will undergo usual treatment as per evidence- and guidelines-based Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC) algorithm (36, 71). Routine non-invasive automated infra-red pupillometry will be performed bilaterally every hour as part of routine neurological checks for neuro-worsening in addition to hourly Glasgow Coma Scale (GCS) score checks and other routine intensive care unit (ICU) protocols. No treatment will be withheld. ICP monitoring will be performed with intra-parenchymal monitor or external ventricular drainage (EVD) as per local protocols.

RISKS TO HUMAN SUBJECTS:

The assessments for this study involve risk and benefits to patients in excess of routine standard of care treatment. The risks related to the intervention i.e. placement of lumbar drain and drainage of CSF, are critical neurological worsening events related to cerebral herniation such as decrease in GCS score, development of new motor deficit, or rarely death. These events will be recorded for all patients and prompt treatment will be instituted accordingly, including an emergent computed tomography (CT) scan (36). Clinical protocols exist at all neurotrauma ICUs for such neuro-worsening events and neurointensivists and neurotrauma surgeons are well placed to manage them medically or surgically in routine care of severe TBI patients.

Background 'Event rate' for critical neuro-worsening events with usual treatment: To estimate background 'event rate' of critical neuro-worsening events, we analyzed the Brain Trauma Foundation (BTF)-New York State TBI-trac® registry from 1997-2004, with 4789 TBI patients, of which 3590 had CT data and 2616 were between the age of 18-65 years. When inclusion / exclusion criteria for age and CT findings were applied, 50.3% of these were eligible for the study. The mean incident risk of having new pupillary asymmetry at any point after admission was 22.0% (95% confidence intervals (CI): 19.9-24.3%), risk of motor worsening was 18.0% (95% CI: 12.6-25.0%) for those with motor score 1-4, and 16.4% (95% CI: 12.1-21.9%) for all motor scores with deterioration. Finally, risk of 2-week mortality was 22.4% (95% CI 20.2-24.8%). This data provides us with an expected event rate, though the comparison will still be made between control and intervention arms of the study, per protocol. Given the high incidence of these events occurring as natural history of the disease, they will be classified as anticipated Serious adverse events (SAEs).

Human Subjects Protections:

Pressure and Volume protected lumbar CSF drainage: In the studies reviewed, ELD was set to drain at 0-20 mmHg or drained at fixed volume. In order to increase safety, we will perform ELD in patients without high ICP at 15 mmHg and those with high ICP at 20 mmHg and additionally volume-limit drainage to 10 ml/hour.

Procedure safety:

Indication:

ELD will be utilized as the first intervention in the 2nd tier of SIBICC protocol, which will invariably be preceded by gradual increase in ICP. As per SIBICC protocol, a CT scan will be obtained prior to advancement to 2nd tier and ELD placement.

Contra-indications:

ELD will NOT be utilized to lower ICP during sudden ICP crises associated with neuro-worsening. Hypertonic saline, mannitol, hyperventilation, and review for surgery will be utilized as per clinical routine.

ELD will NOT be placed in lieu of an EVD. ELD will NOT be performed in patients undergoing hemicraniectomy.

Safety Monitoring: Given the greatest risk of neuro-worsening from herniation is soon after drainage is commenced, all patients will undergo automated pupillometry for pupillary size, symmetry, light reactivity and neurological pupillary index (NPI) every 15 minutes for 1 hour following ELD placement and start of CSF drainage. Following the first hour, pupillometry will be performed hourly. If NPI drops by 1 point within the 1st hour, a head CT may be obtained to review any craniocaudal shift.

SAFETY REPORTING: All unanticipated SAEs will be reported to the steering committee, local site institutional research boards (IRBs) as well as the overall IRB, within 24 hours. Anticipated SAE and adverse events (AEs) will be reported in annual reports.

Data Safety and Monitoring Board (DSMB):

A DSMB of a pool of 7 experienced trauma neurosurgeons and neurointensivists of international standing, will review every neuro-worsening events, as defined above, in each arm of the study. The DSMB will meet every 6 months to review anticipated SAEs. DSMB will review unanticipated SAE including deaths within 48 hours, and will make determinations of association of unanticipated adverse events with interventions.

Potential benefits of the proposed research to participants:

As this is an interventional study, the research participants may gain direct benefit or suffer harm. At conclusion of the study, the overall results will be included in a summary report mailed to all participants. In the field of TBI management, this study has potential benefits in treating post-traumatic intracranial hypertension, which is the main mechanism of neurological deterioration following severe TBI and improving functional outcome for participants.

Being tested
External Lumbar drainage
Keywords
Traumatic brain injury, intracranial pressure, intracranial hypertension, lumbar drainage
Medical subject headings
Brain Injuries, Traumatic, Intracranial Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • External Lumbar drainageProcedure or surgery

    ELD @ 15 or 20mmHg based on intervention arm with maximum of 10ml/hour drainage

Study groups in NCT05889650
Study groupRoleWhat they receive
1st stage - prophylacticExperimentalExternal lumbar drainage @15mmHg if intracranial pressure is not raised on admission
Receives: Procedure: External Lumbar drainage
2nd stage - treatmentExperimentalExternal lumbar drainage @20mmHg if / when intracranial pressure >20mmHg and tier 1 therapies cannot achieve ICP<20mmHg
Receives: Procedure: External Lumbar drainage
Usual treatmentNo interventionUsual treatment as per SIBICC algorithm

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety of ELD in selected Severe TBI patients

    Rate of occurrence of herniation events or death in 3 arms

    Measured: 10 days

  2. Feasibility of ELD in selected Severe TBI patients

    Proportion of patients able to undergo treatment as per randomised arm

    Measured: 10 days

Secondary outcomes (2)
  1. Reduction in ICP burden using ELD in selected severe TBI patients

    Total number of hours with ICP>20mmHg

    Measured: 10 days

  2. Utility of automated pupillometry to predict safety of ELD

    worsening of Pupillometry based reactivity index in 6 hours preceding herniation events with occurrence of such events

    Measured: 10 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jun 2023
  2. Study start24 Jun 2024
  3. Primary completion15 Jun 2028 (estimated)
  4. Study completion30 Jun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Sequential
Model description
2-stage randomization
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05889650
Sponsor's protocol ID
23-17380
Acronym
ELASTIC
Status last verified
Apr 2026
First submitted
20 May 2023
Last updated
22 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Badhiwala J, Lumba-Brown A, Hawryluk GWJ, Ghajar J. External Lumbar Drainage following Traumatic Intracranial Hypertension: A Systematic Review and Meta-Analysis. Neurosurgery. 2021 Aug 16;89(3):395-405. doi: 10.1093/neuros/nyab181.

    PubMed 34171100
  • Ginalis EE, Fernandez LL, Avila JP, Aristizabal S, Rubiano AM. A review of external lumbar drainage for the management of intracranial hypertension in traumatic brain injury. Neurochirurgie. 2022 Feb;68(2):206-211. doi: 10.1016/j.neuchi.2021.05.004. Epub 2021 May 26.

    PubMed 34051245
  • Bauer M, Sohm F, Thome C, Ortler M. Refractory intracranial hypertension in traumatic brain injury: Proposal for a novel score to assess the safety of lumbar cerebrospinal fluid drainage. Surg Neurol Int. 2017 Nov 1;8:265. doi: 10.4103/sni.sni_98_17. eCollection 2017.

    PubMed 29184716
  • Llompart-Pou JA, Abadal JM, Perez-Barcena J, Molina M, Brell M, Ibanez J, Raurich JM, Ibanez J, Homar J. Long-term follow-up of patients with post-traumatic refractory high intracranial pressure treated with lumbar drainage. Anaesth Intensive Care. 2011 Jan;39(1):79-83. doi: 10.1177/0310057X1103900113.

    PubMed 21375095
  • Murad A, Ghostine S, Colohan AR. A case for further investigating the use of controlled lumbar cerebrospinal fluid drainage for the control of intracranial pressure. World Neurosurg. 2012 Jan;77(1):160-5. doi: 10.1016/j.wneu.2011.06.018. Epub 2011 Nov 15.

    PubMed 22154151
  • Abadal-Centellas JM, Llompart-Pou JA, Homar-Ramirez J, Perez-Barcena J, Rossello-Ferrer A, Ibanez-Juve J. Neurologic outcome of posttraumatic refractory intracranial hypertension treated with external lumbar drainage. J Trauma. 2007 Feb;62(2):282-6; discussion 286. doi: 10.1097/01.ta.0000199422.01949.78.

    PubMed 17297313
  • Tuettenberg J, Czabanka M, Horn P, Woitzik J, Barth M, Thome C, Vajkoczy P, Schmiedek P, Muench E. Clinical evaluation of the safety and efficacy of lumbar cerebrospinal fluid drainage for the treatment of refractory increased intracranial pressure. J Neurosurg. 2009 Jun;110(6):1200-8. doi: 10.3171/2008.10.JNS08293.

    PubMed 19249925
  • Hawryluk GWJ, Aguilera S, Buki A, Bulger E, Citerio G, Cooper DJ, Arrastia RD, Diringer M, Figaji A, Gao G, Geocadin R, Ghajar J, Harris O, Hoffer A, Hutchinson P, Joseph M, Kitagawa R, Manley G, Mayer S, Menon DK, Meyfroidt G, Michael DB, Oddo M, Okonkwo D, Patel M, Robertson C, Rosenfeld JV, Rubiano AM, Sahuquillo J, Servadei F, Shutter L, Stein D, Stocchetti N, Taccone FS, Timmons S, Tsai E, Ullman JS, Vespa P, Videtta W, Wright DW, Zammit C, Chesnut RM. A management algorithm for patients with intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC). Intensive Care Med. 2019 Dec;45(12):1783-1794. doi: 10.1007/s00134-019-05805-9. Epub 2019 Oct 28.

    PubMed 31659383

Questions about this trial

What is this clinical trial studying?

A study testing External Lumbar drainage in people with Severe Traumatic Brain Injury and Intracranial Hypertension, run by Brain Trauma Foundation at 6 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 22 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 6 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Carlos Morales, MPH (240-6536638, carlos.morales.ctr@usuhs.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety of ELD in selected Severe TBI patients (time frame: 10 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05889650, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2026; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in